Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00726726 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study With a Potential Alzheimer's Disease Compound
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00726726 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 22 participants.
The verdict
NCT00726726, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BMS-708163 will effect the pharmacokinetics of the commonly prescribed medicines midazolam, warfarin, caffeine,omeprazole and dextromethorphan
Interventions
- DRUG BMS-708163
- DRUG Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)
- DRUG BMS-708163 + Cooperstown Cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-08 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00726726
The ClinicalTrials.gov registry entry for NCT00726726 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BMS-708163 is the first listed.
NCT00726726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00726726 about?
NCT00726726 is a clinical study titled "Drug Interaction Study With a Potential Alzheimer's Disease Compound". The purpose of this study is to determine whether BMS-708163 will effect the pharmacokinetics of the commonly prescribed medicines midazolam, warfarin, caffeine,omeprazole and dextromethorphan
What is the current status of trial NCT00726726?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2008-08. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00726726?
The interventions under investigation include: BMS-708163 (DRUG), Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan) (DRUG), BMS-708163 + Cooperstown Cocktail (DRUG).
Who is sponsoring clinical trial NCT00726726?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.